MCM
MRNA icon

Manchester Capital Management’s Moderna MRNA Stock Holding History

Manchester Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.5K Sell
321
-51
-14% -$2.64K ﹤0.01% 666
2026
Q1 		$18.9K Buy
372
+60
+19% +$2.8K ﹤0.01% 687
2025
Q4 		$9.2K Buy
312
+296
+1,850% +$8.04K ﹤0.01% 802
2025
Q3 		$414 Sell
16
-150
-90% -$4.18K ﹤0.01% 1211
2025
Q2 		$4.58K Buy
166
+64
+63% +$1.69K ﹤0.01% 917
2025
Q1 		$2.89K Buy
102
+33
+48% +$1.17K ﹤0.01% 966
2024
Q4 		$2.87K Sell
69
-7
-9% -$335 ﹤0.01% 962
2024
Q3 		$5.08K Sell
76
-118
-61% -$10.8K ﹤0.01% 886
2024
Q2 		$23K Buy
194
+82
+73% +$10.4K ﹤0.01% 640
2024
Q1 		$11.9K Sell
112
-152
-58% -$15.3K ﹤0.01% 614
2023
Q4 		$26.3K Buy
264
+34
+15% +$2.86K ﹤0.01% 499
2023
Q3 		$23.8K Buy
230
+162
+238% +$18.1K ﹤0.01% 508
2023
Q2 		$8.26K Hold
68
– – ﹤0.01% 561
2023
Q1 		$10.4K Hold
68
– – ﹤0.01% 536
2022
Q4 		$12.2K Hold
68
– – ﹤0.01% 447
2022
Q3 		$8K Hold
68
– – ﹤0.01% 470
2022
Q2 		$10K Hold
68
– – ﹤0.01% 490
2022
Q1 		$12K Sell
68
-373
-85% -$62.8K ﹤0.01% 518
2021
Q4 		$112K Buy
441
+124
+39% +$36.3K 0.01% 328
2021
Q3 		$122K Buy
317
+249
+366% +$91.8K 0.02% 336
2021
Q2 		$16K Hold
68
– – ﹤0.01% 460
2021
Q1 		$9K Buy
68
+59
+656% +$8.55K ﹤0.01% 491
2020
Q4 		$1K Buy
9
+4
+80% +$405 ﹤0.01% 668
2020
Q3 		$0 Sell
5
-2,638
-100% -$184K ﹤0.01% 639
2020
Q2 		$170K Buy
2,643
+927
+54% +$50.8K 0.02% 250
2020
Q1 		$51K Buy
+1,716
New +$39.5K 0.01% 353

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Manchester Capital Management's MRNA Position: Q2 2026 in Review

Manchester Capital Management reduced its Moderna (MRNA) stake by 14% in Q2 2026, selling an estimated $2.64K and leaving 321 shares worth $22.5K. The position accounts for ﹤0.01% of the portfolio, ranked #666.

Manchester Capital Management first reported a position in MRNA in Q1 2020 and has held it in 26 quarters since. The position peaked at $170K in Q2 2020. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Manchester Capital Management held 321 shares of Moderna worth $22.5K as of Q2 2026.
  • Manchester Capital Management sold 51 Moderna shares in Q2 2026, an estimated $2.64K.
  • Moderna made up ﹤0.01% of Manchester Capital Management's portfolio in Q2 2026, its #666 holding.
  • Manchester Capital Management first reported a position in Moderna in Q1 2020 and has held it in 26 quarters since.
  • Manchester Capital Management's Moderna position peaked at $170K in Q2 2020.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.